Prospective IL-6 Levels and SLE Flare Risk, 188 Patients 2017–2023

A 2017–2023 prospective, longitudinal study of 188 adult patients with systemic lupus erythematosus (SLE) by Borja del Carmelo Gracia Tello. It examines serum interleukin-6 (IL-6) levels as a predictor of short-term disease flare, comparing its performance to anti-dsDNA antibodies and complement components C3 and C4.

Use Cases

• Predicting short-term disease flare in SLE patients based on elevated IL-6 levels.
• Comparing biomarker discriminative performance using ROC analyses and multivariable models.
• Analyzing associations between IL-6 levels and specific organ manifestations like arthritis or nephritis.
• Building longitudinal risk assessment models adjusted for clinical confounders.

Strengths

• Prospective, longitudinal design with data collected from 2017 to 2023.
• Includes 188 adult SLE patients with disease activity assessed using SLEDAI-2K.
• Compares IL-6 against established biomarkers (anti-dsDNA, C3, C4) using statistical methods like log-rank test and ROC analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Single-center study design may limit generalizability.

Provenance

Source

Borja del Carmelo Gracia Tello via figshare

Collection Method

Prospective, longitudinal, single-center clinical study.

Time Range

2017–2023

Freshness

Last updated 2026-05-08 05:54:19; freshness should be verified.

Geography

null